Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :2025
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1452    
    Printed40    
    Emailed0    
    PDF Downloaded239    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 

 GYNAECOLOGY ONCOLOGY SYMPOSIUM: ORIGINAL ARTICLE
Year : 2014  |  Volume : 51  |  Issue : 3  |  Page : 315-318

Elevated chromogranin A serum levels in ovarian carcinoma patients


1 Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, Via Messina 829, University of Catania, I 95126 Catania, Italy
2 Department of Obstetrics and Gynaecology, Policlinico Hospital, Via S. Sofia 78, University of Catania, I-95123 Catania, Italy
3 Department of General Surgery, Section of General Surgery and Oncology, Vittorio Emanuele Hospital, Via Plebiscito 628, University of Catania, I-95123 Catania, Italy
4 Department of Biomedical Sciences, Via Androne 83, University of Catania, I-95124 Catania, Italy

Correspondence Address:
M Malaguarnera
Department of Senescence, Urological and Neurological Sciences, Cannizzaro Hospital, Via Messina 829, University of Catania, I 95126 Catania
Italy
Login to access the Email id

Source of Support: This study was supported by a grant from MURST (Ministero dell’Università e Ricerca Scientifica e Tecnologica)., Conflict of Interest: None


DOI: 10.4103/0019-509X.146776

Rights and Permissions

Background: The observation of neuroendocrine activity during clinical course of ovarian cancer, suggested the use of neuroendocrine serum markers to detect this tumor. Aim: To evaluate the usefulness of serum measurements of chromogranin A (CgA) in the various stages of ovarian cancer. Materials and Methods: We measured serum concentrations of CgA and cancer antigen 125 (CA125) in 79 women at different clinical stages of ovarian cancer, enrolled between 2000 and 2007, and in a control group of 50 female volunteers. Results: CgA showed increased levels in patients with ovarian cancer as compared with healthy subjects, as it has been seen for CA125 serum levels. We also observed significant increase in CgA and CA125 serum levels when comparing patients with ovarian cancer in stage I versus stage II (P < 0.001); stage I versus stage III (P < 0.001); stage I versus stage IV (P < 0.001); stage II versus stage III (P < 0.001); stage II versus stage IV (P < 0.001). In patients with ovarian carcinoma in stage IV we observed a correlation between CgA and CA125 with a difference of 0.718 (P < 0.001). Conclusions: CgA serum levels were elevated in ovarian cancer and increased with the stage. Further studies are needed to elucidate the role of CgA as a prognostic indicator during treatment for ovarian cancer.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow